Hospital
Hca Health Services of Tennessee, INC.
Hca Health Services of Tennessee, INC. was paid $45.89M by Medicaid between Jan 2018 and Dec 2024, across 106 billing codes. Its largest line is 99283, emergency room visit (moderate) — 48% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF TENNESSEE, INC.
NASHVILLE, TN 37203
NASHVILLE, TN 37203
33aNPI1023055126assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$45.89M
24GClaims453,999
24DCodes billed106
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#4 of 71
Median peer was paid$6.96M
This provider vs. median6.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 71,882 | $7.16M | |
| 2019 | 74,942 | $7.33M | |
| 2020 | 54,618 | $5.09M | |
| 2021 | 64,707 | $6.29M | |
| 2022 | 74,718 | $7.38M | |
| 2023 | 71,428 | $7.09M | |
| 2024incomplete | 41,704 | $5.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 48% | 81,722 | 74,353 | $22.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 55,502 | 47,719 | $15.83M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.2% | 21,918 | 21,349 | $4.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 20,941 | 17,508 | $899K |
| G0378 | Hospital observation service, per hour | 1.6% | 974 | 843 | $720K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 1,100 | 978 | $674K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 3,346 | 3,294 | $549K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,986 | 1,687 | $145K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,385 | 4,189 | $141K |
| 63685 | <1% | 19 | 12 | $124K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 300 | 259 | $98K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,483 | 5,421 | $61K |
94 more codes
| 95813 | <1% | 412 | $53K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 48 | $43K |
| 80053 | Comprehensive metabolic panel | <1% | 38,356 | $32K |
| 85027 | <1% | 59,632 | $29K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,738 | $26K |
| 80069 | <1% | 944 | $23K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 457 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,498 | $22K |
| 82248 | <1% | 2,112 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,282 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,396 | $10K |
| 85610 | <1% | 3,205 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 137 | $6K |
| 80076 | <1% | 3,616 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 792 | $6K |
| 83735 | <1% | 1,842 | $6K | |
| 77334 | <1% | 21 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,678 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 170 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,233 | $2K |
| 74246 | <1% | 14 | $1K | |
| 85045 | <1% | 745 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,233 | $1K |
| 77072 | <1% | 27 | $942.06 | |
| 84702 | <1% | 943 | $908.97 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 88 | $898.80 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 753 | $668.20 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,862 | $632.34 |
| 84100 | <1% | 215 | $590.74 | |
| 81003 | <1% | 22,492 | $407.74 | |
| 85730 | <1% | 760 | $305.60 | |
| 83690 | <1% | 10,851 | $267.52 | |
| 84484 | <1% | 8,466 | $219.11 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $173.74 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,502 | $110.10 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,523 | $110.08 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,074 | $98.50 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 713 | $95.69 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,640 | $91.67 |
| 87070 | <1% | 1,265 | $89.52 | |
| 86140 | <1% | 38 | $83.05 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 344 | $74.45 |
| 80179 | <1% | 297 | $65.23 | |
| 80143 | <1% | 296 | $65.23 | |
| 84703 | <1% | 2,472 | $62.62 | |
| 82077 | <1% | 433 | $60.46 | |
| 81025 | <1% | 6,153 | $54.69 | |
| 83615 | <1% | 19 | $43.37 | |
| 87430 | <1% | 2,193 | $39.70 | |
| 86850 | <1% | 434 | $28.38 | |
| 86900 | <1% | 550 | $22.85 | |
| 86901 | <1% | 550 | $22.85 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $18.15 |
| 87581 | <1% | 12 | $18.15 | |
| 87486 | <1% | 12 | $18.15 | |
| 82553 | <1% | 33 | $18.13 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,028 | $12.35 |
| 87210 | <1% | 3,871 | $8.14 | |
| 81001 | <1% | 4,974 | $7.82 | |
| S3600 | Stat laboratory request (situations other than s3601) | <1% | 54 | $0.37 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 826 | $0.36 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 98 | $0.00 |
| 98960 | 0% | 111 | $0.00 | |
| 88312 | 0% | 334 | $0.00 | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 0% | 102 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 284 | $0.00 |
| 94664 | 0% | 284 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 143 | $0.00 |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | 0% | 41 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 25 | $0.00 |
| 31720 | 0% | 44 | $0.00 | |
| 85014 | 0% | 30 | $0.00 | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 0% | 137 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 18 | $0.00 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 0% | 15 | $0.00 |
| 74018 | 0% | 12 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 12 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 69 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 2,132 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 524 | $0.00 |
| 76801 | 0% | 763 | $0.00 | |
| 82550 | 0% | 52 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 246 | $0.00 |
| 83880 | 0% | 208 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 519 | $0.00 |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 18 | $0.00 |
| 82657 | 0% | 463 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 78 | $0.00 |
| 87807 | 0% | 12 | $0.00 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 27 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 86 | $0.00 |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 0% | 44 | $0.00 |
| 83605 | 0% | 26 | $0.00 | |
| C1769 | Guide wire | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMAS, JACKSON (CFO)